Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)

Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.

Who May Be Eligible (Plain English)

Who May Qualify: - Fulfilment of the ACR/EULAR Classification Criteria for rheumatoid arthritis (RA) - Fulfilment of the American College of Rheumatology criteria for chronic widespread pain - Stable disease (swollen joint count ≤1 and CRP ≤10) - Has normal or corrected to normal vision and hearing abilities - Right-handed (to reduce baseline motor response test heterogeneity) - Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable) Who Should NOT Join This Trial: - Unable to understand the task. - Unable to provide a written willing to sign a consent form. - Unable to understand English. - Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease) - Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc) - Under active management of pain team (changing medications, other non pharmacological pain treatment) - Involved in other interventional experimental studies Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Fulfilment of the ACR/EULAR Classification Criteria for rheumatoid arthritis (RA) * Fulfilment of the American College of Rheumatology criteria for chronic widespread pain * Stable disease (swollen joint count ≤1 and CRP ≤10) * Has normal or corrected to normal vision and hearing abilities * Right-handed (to reduce baseline motor response test heterogeneity) * Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable) Exclusion Criteria: * Unable to understand the task. * Unable to provide a written informed consent. * Unable to understand English. * Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease) * Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc) * Under active management of pain team (changing medications, other non pharmacological pain treatment) * Involved in other interventional experimental studies

Treatments Being Tested

PROCEDURE

Neurofeedback

A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen

Locations (1)

Clinical Research Facility (CRF), Queen Elizabeth University Hospital
Glasgow, Scotland, United Kingdom